OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

OCX stock results show that OncoCyte missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

The post OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023 appeared first on InvestorPlace.

• The #1 AI Investment Might Be This Company You’ve Never Heard Of
• Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
• It doesn’t matter if you have $500 or $5 million. Do this now.